We propose that immunocompetent patients in the acute phase of infection represent the optimal population for maximizing the diagnostic utility of MxA in distinguishing respiratory viral infections, whereas relying solely on MxA testing to exclude viral infections in immunosuppressed ARI patients is not advisable due to its limited sensitivity. This evidence concerns the gene MX1 and infection.